medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número S1

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (S1)


Module XVll
Treatment of hepatitis C before and after liver transplantation

Moreno AR

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 63-66
Archivo PDF: 41.66 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-78.

  2. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9(Suppl.3): S1-S9.

  3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9(Suppl.3): S28-S34.

  4. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl 3): S58-S62.

  5. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.

  6. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.

  7. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-74.

  8. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.

  9. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.

  10. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41.

  11. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32: 852-8.

  12. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-56.

  13. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl 2003; 9(Suppl.3): S44-S47.

  14. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl.3): S58-S62.

  15. McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003; 9(Suppl.3): S21-S27.

  16. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63-S66.

  17. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol 2005; 42: 456-62.

  18. Crippin JS, Sheiner P, Terrault NA, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 2002; 8: 350-5.

  19. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9(Suppl.3): S90-S94.

  20. Thomas RM, Brenns JJ, Guzmán-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.

  21. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.

  22. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus infected patients undergoing liver transplantation. Liver Transpl 2003; 9: S95-S100.

  23. Sheiner P, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-38.

  24. Singh N, Gayowski T, Wannstedt C, Shakil O, Wagener M, Fung J, et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65: 82-6.

  25. Mazzaferro V, Tagger A, Schiavo M, Regalia A, Pulvirenti M, Ribero J, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001; 33: 1355-7.

  26. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher N, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transpl 2005; 5: 118-124.

  27. Berenguer M, Prieto M, Palau A, Carrasco D, Rayon JM, Calvo F, Berenguer J. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16(11): 1207-12.

  28. Ross AS, Bhan AK, Pascual M, Thiim M, Cosimi AB, Chung RT. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-73.

  29. Dumortier J, Scoaxec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol 2004; 40: 669-74.

  30. Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with a combination of pegylated interferon alfa 2b and ribavirin: an open label series. Transplantation 2004; 77: 190-4.

  31. Neff GW, Montalbano M, O’Brien C, Nishida S, Dafdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-7.

  32. Todd-Stravitz R, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850-8.

  33. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-67.

  34. Bizollon T, Admed SNS, Radenne S, Chevallier M, Chevallier P, Paraz P, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 2003; 52: 283-7.

  35. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199-207.




2020     |     www.medigraphic.com